Baird Maintains an 'Outperform' on Celgene (CELG); Revlimid U.S. Uptake Survey More Mixed
Tweet Send to a Friend
Baird maintains an 'Outperform' on Celgene (NASDAQ: CELG) price target of $78.00.
Analyst, Christopher J. Raymond, said, "Continue to ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Analyst, Christopher J. Raymond, said, "Continue to ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
